Fluorescent magnetic nanoprobes, methods of making, and methods of use
US-2016279270-A1 · Sep 29, 2016 · US
Diagnostic compounds for targeting a chemokine receptors
US9402924B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9402924-B2 |
| Application number | US-66354805-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 23, 2005 |
| Priority date | Sep 23, 2004 |
| Publication date | Aug 2, 2016 |
| Grant date | Aug 2, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a compound comprising, firstly a component for targeting at least one chemokine receptor and, secondly, a detection component capable of being identified by a medical imaging method.
First claim
Opening claim text (preview).
The invention claimed is: 1. A molecule comprising, firstly, a CXCR4-receptor-targeting component which is non-complexed AMD3100, and, secondly, a detection component capable of being identified by a medical imaging method, in which the detection component is at least one linear or macrocyclic chelate of an ion of a paramagnetic metal or of a radionucleide or a shift metal, wherein the chelate is selected from the group consisting of DTPA, DTPA BMA, DTPA BOPTA, DO3A, TETA, TRITA, HETA, DOTA, NOTA and PCTA. 2. The molecule of claim 1 in which the chelate is PCTA. 3. A diagnostic composition comprising the molecule according to claim 1 and a pharmaceutically acceptable carrier. 4. Method for the diagnosis of a pathology associated with an overexpression or an underexpression of CXCR4 receptors, comprising the administration of an effective amount of a molecule according to claim 1 to a patient in need thereof. 5. Method for the diagnosis of a pathology associated with an overexpression or an underexpression of CXCR4 receptors, comprising the administration of an effective amount of a composition according to claim 3 to a patient in need thereof. 6. The method of claim 5 in which the pathology is tumour. 7. The method of claim 5 in which the pathology is tumour metastases.
Assignees
Inventors
Classifications
the organic macromolecular compound being polyethyleneglycol [PEG] · CPC title
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title
Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title
conjugated systems · CPC title
specific for leukemia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9402924B2 cover?
- The present invention relates to a compound comprising, firstly a component for targeting at least one chemokine receptor and, secondly, a detection component capable of being identified by a medical imaging method.
- Who is the assignee on this patent?
- Port Marc, Guerbet Sa
- What technology area does this patent fall under?
- Primary CPC classification A61K49/1866. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).